Phaseline

Companies › CatalYm

CatalYm: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Visugromab (CTL-002)
GDF-15 neutralizing antibody
GDF15Phase 2Metastatic Non-Squamous Non-Small Cell Lung Cancer; Unresectable or Metastatic Hepatocellular Carcinoma; Cancer-associated Cachexia; Solid Tumor, AdultApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04725474Visugromab (CTL-002)Phase 1Solid Tumor, AdultOncologyApr 2028
NCT07098988Visugromab (CTL-002)Phase 2Metastatic Non-Squamous Non-Small Cell Lung CancerOncologyMar 2029
NCT07219459Visugromab (CTL-002)Phase 2Unresectable or Metastatic Hepatocellular CarcinomaOncologySep 2029
NCT07246863Visugromab (CTL-002)Phase 2Metastatic Non-Squamous Non-Small Cell Lung CancerOncologyOct 2029
NCT07112196Visugromab (CTL-002)Phase 2Cancer-associated CachexiaOncologyDec 2029

Targets

GDF15 (1)

Companies with the same targets

Kexing Biopharm AVEO Pharmaceuticals Pfizer

Companies built like this

Alethia Biotherapeutics Solstice Oncology CrystalGenomics Partner Therapeutics STCube

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.